Roche | pharmaphorum

Wednesday 22 July 2026

Roche

News

Roche gets EU nod for kidney disease algorithm

Roche and Klinrisk have picked up a CE-mark for an AI tool that can be used to predict renal function decline in patients with chronic kidney disease.

News

Jazz, Roche combo cleared by FDA for lung cancer

Jazz, Roche combo cleared by FDA for lung cancer

Can FDA approval of Jazz Pharma's Zepzelca in a combination regimen for extensive-stage small cell lung cancer return sales of the drug to growth?

News

Roche's oral SERD comes good in 2nd-line breast cancer trial

Roche's oral SERD comes good in 2nd-line breast cancer trial

Roche has staked a claim to use its oral SERD giredestrant as a second-line therapy for breast cancer, regardless of a patient's ESR1 mutation status.

News

Roche and 89bio logos

Roche poised to buy MASH drug developer 89bio for $3.5bn

Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its phase 3 candidate pegozafermin for MASH.

News

Ametris starts obesity digital endpoint project with pharma

Ametris launches a collaboration with pharma companies that aims to show how digital endpoints can be used in obesity trials.

News

Roche HQ

OMass attracts $420m Roche wager on IBD programme

UK biotech OMass has revealed its first major pharma partnership, with Roche paying $20m upfront for an inflammatory bowel disease programme.